AAVantgarde Presents Positive Preclinical Data in Large Animal Models from its Stargardt Disease Program in an Oral Presentation at the ASGCT 2024 Annual Meeting April 23, 2024
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic June 6, 2023
